Company research
Cingulate Inc.
CIK 1862150Updated Sep 24, 2026
Name history
Cingulate Inc. · through Aug 13, 2026
CING price & chart
Loading TradingView…
NASDAQ:CING on TradingView ↗About the company
We are a biopharmaceutical company using our proprietary Precision Timed ReleaseTM (PTRTM) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (“ADHD”) and anxiety, we are identifying and evaluating additional therapeutic areas where our PTR technology may be employed to develop future product candidates. Our PTR platform incorporates a proprietary Erosion Barrier Layer (“EBL”) designed to allow for the release of drug substance at specific, pre-defined time intervals, unlocking the potential for once-daily, multi-dose tablets. We believe there remains a significant, unmet need within the current treatment paradigm for true once-daily ADHD stimulant medications with lasting duration and a superior side effect profile to better serve the needs of patients throughout their entire active-day.
In the news
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
S-8 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
DEF 14A filing
ARS filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 15,073,263Source | 14,864,489Source | 3,491,436Source | 11,405,057Source |
| Property, Plant and Equipment, NetUSD | 1,725,919Source | 2,104,675Source | 2,545,965Source | 2,904,787Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 10,953,383Source | 12,211,321Source | 52,416Source | 5,356,276Source |
| Assets, CurrentUSD | 12,008,258Source | 12,660,803Source | 578,594Source | 7,869,652Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,046,862Source | 423,157Source | 511,556Source | 2,278,944Source |
| Operating Lease, Right-of-Use AssetUSD | 1,339,086Source | 99,011Source | 366,877Source | 630,618Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 12,564,356Source | 7,408,984Source | 10,360,865Source | 7,523,035Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 725Source | 340Source | 118Source | 1,131Source |
| Additional Paid in CapitalUSD | 134,883,213Source | 115,944,345Source | 86,073,896Source | 73,289,387Source |
| Retained Earnings (Accumulated Deficit)USD | -132,375,031Source | -108,489,180Source | -92,943,443Source | -69,408,496Source |
| Stockholders' Equity Attributable to ParentUSD | 2,508,907Source | 7,455,505Source | -6,869,429Source | 3,882,022Source |
| Liabilities and EquityUSD | 15,073,263Source | 14,864,489Source | 3,491,436Source | 11,405,057Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 10,312,625Source | 4,972,105Source | 10,225,766Source | 7,012,800Source |
| Operating Lease, Liability, CurrentUSD | 238,864Source | 130,662Source | 358,085Source | 339,755Source |
| Accounts Payable, CurrentUSD | 2,035,685Source | 1,270,280Source | 5,199,105Source | 762,357Source |
| Operating Lease, Liability, NoncurrentUSD | 1,100,222Source | — | 130,663Source | 488,748Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,742,116Source | 1,039,625Source | 1,651,519Source | 894,635Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,523,828Source | 995,484Source | 812,670Source | 800,796Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -17,245,182Source | -18,451,387Source | -15,034,543Source | -15,882,808Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -162,138Source | -211,800Source | -224,096Source | -152,652Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | — | 165Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 162,138Source | 211,800Source | 224,096Source | 153,420Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 16,149,382Source | 30,822,092Source | 9,954,779Source | 4,898,991Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -1,257,938Source | 12,158,905Source | -5,303,860Source | -11,136,469Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 19,895Source | 6,288Source | 19,421Source | 19,000Source |
| Additional Financial Items | ||||
| Amortization of Debt Issuance CostsUSD | 26,525Source | — | — | — |
| DepreciationUSD | 540,894Source | 653,090Source | 582,918Source | 394,011Source |
| Gain (Loss) on Extinguishment of DebtUSD | -805,951Source | — | — | — |
| General and Administrative ExpenseUSD | 10,164,051Source | 6,199,708Source | 7,265,885Source | 8,506,438Source |
| Net Income (Loss) Attributable to ParentUSD | -22,449,911Source | -15,545,737Source | -23,534,947Source | -17,676,232Source |
| Nonoperating Income (Expense)USD | — | 99,236Source | -775,758Source | -174,514Source |
| Proceeds from Issuance of Common StockUSD | 10,153,812Source | 25,875,168Source | 6,970,826Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -19,938,108Source | -15,644,973Source | -22,759,189Source | -17,501,718Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -22,449,911Source | -15,545,737Source | -23,534,947Source | -17,676,232Source |
| Net Income (Loss) Attributable to ParentUSD | -22,449,911Source | -15,545,737Source | -23,534,947Source | -17,676,232Source |
| Earnings Per Share, BasicUSD per share | -4.44Source | -10.2Source | -26Source | -1.56Source |
| Earnings Per Share, DilutedUSD per share | -4.44Source | -10.2Source | -26Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 5,055,329Source | 1,524,797Source | 905,225Source | 11,309,412Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 5,055,329Source | 1,524,797Source | 905,225Source | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 10,164,051Source | 6,199,708Source | 7,265,885Source | 8,506,438Source |
| Interest ExpenseUSD | — | — | 790,000Source | 292,339Source |
| Interest Expense, DebtUSD | 901,325Source | — | — | — |
| Interest Income (Expense), NetUSD | -1,361,130Source | — | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | -1,361,130Source | — | — | — |
| Interest Income, OtherUSD | 369,267Source | — | — | — |
| Nonoperating Income (Expense)USD | — | 99,236Source | -775,758Source | -174,514Source |
| Research and Development ExpenseUSD | 9,774,057Source | 9,445,265Source | 15,493,304Source | 8,995,280Source |
Offerings
Registration 333-288877
Filing attachments
ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness Cash and Cash Equivalents of $28.4 Million as of June 30, 2026 Providing Runway Through Mid-2027; Company Advances Chemistry, Manufacturing and Controls (CMC) Work Toward NDA Resubmission KANSAS CITY, Kan., August 13, 2026 (GLOBE NEWSWIRE) - Cingulate Inc. (NASDAQ: CING), a biopharmaceutical co…
Read attachment ↗ex99-1.htm · 8-K · 2026-07-02
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E® CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional Investors KANSAS CITY, Kan., July 2, 2026 - Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has…
Read attachment ↗ex99-1.htm · 8-K · 2026-06-16
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301 Exclusivity Extended into December 2042 Kansas City, Kan., June 16, 2026 - Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead…
Read attachment ↗ex99-1.htm · 8-K · 2026-06-02
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Cingulate Receives Complete Response Letter from FDA for CTx-1301 No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on CMC-Related Requests Company Plans Prompt Response and Submission of Requested Information Company is Well Capitalized with Nearly $30 Million Cash on Hand KANSAS CITY, Kan., June 2, 2026 - Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-14
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301 Cash Position Grows to $25.9 Million KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported fin…
Read attachment ↗ex99-1.htm · 8-K · 2026-03-18
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights U.S. Patent Notice of Allowance for CTx-1301 Received; Additional European Patents Granted Recent $12M Private Placement Closed At-the-Market Pricing KANSAS CITY, Kan., March 18, 2026 -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline…
Read attachment ↗